Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 22, 2014

EMD Millipore Inks Biomanufacturing Deal with Samsung BioLogics

  • EMD Millipore and Samsung BioLogics signed a Memorandum of Understanding (MOU) for a strategic alliance to encompass a long-term supply agreement in which EMD Millipore will provide raw materials for biopharmaceutical manufacturing.

    “Our latest partnership in the biopharmaceutical sector will further strengthen the great relationship built in other business areas for the past years. It will also help us support Samsung’s initiative in the CMO and biopharmaceutical field,” said Udit Batra, Ph.D., president and CEO of EMD Millipore.

    EMD Millipore will become an essential raw material supplier for Samsung BioLogics’ 30 KL facility as well as its new 150 KL facility that is expected to be completed in 2015 at Songdo, Incheon, Korea.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »